Getein Biotech Inc (603387) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Getein Biotech Inc (603387) has a cash flow conversion efficiency ratio of 0.036x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥100.90 Million ≈ $14.76 Million USD) by net assets (CN¥2.80 Billion ≈ $409.92 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Getein Biotech Inc - Cash Flow Conversion Efficiency Trend (2012–2024)
This chart illustrates how Getein Biotech Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Getein Biotech Inc debt and liabilities for a breakdown of total debt and financial obligations.
Getein Biotech Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Getein Biotech Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Banco do Estado do Rio Grande do Sul S.A
SA:BRSR3
|
0.283x |
|
Shenzhen Refond Optoelectronics Co Ltd
SHE:300241
|
0.014x |
|
Media and Games Invest PLC
XETRA:M8G
|
0.001x |
|
Kerjaya Prospek Group Bhd
KLSE:7161
|
0.003x |
|
Yabao Pharmaceutical Group Co Ltd
SHG:600351
|
0.047x |
|
SmartFinancial, Inc.
NYSE:SMBK
|
0.031x |
|
Ocean’s King Lighting Science & Technology Co Ltd
SHE:002724
|
-0.003x |
|
Garware Technical Fibres Limited
NSE:GARFIBRES
|
0.005x |
Annual Cash Flow Conversion Efficiency for Getein Biotech Inc (2012–2024)
The table below shows the annual cash flow conversion efficiency of Getein Biotech Inc from 2012 to 2024. For the full company profile with market capitalisation and key ratios, see 603387 market cap.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | CN¥2.72 Billion ≈ $398.16 Million |
CN¥423.00 Million ≈ $61.90 Million |
0.155x | +27.89% |
| 2023-12-31 | CN¥2.74 Billion ≈ $401.13 Million |
CN¥333.22 Million ≈ $48.76 Million |
0.122x | -32.93% |
| 2022-12-31 | CN¥2.66 Billion ≈ $389.91 Million |
CN¥482.96 Million ≈ $70.67 Million |
0.181x | -4.67% |
| 2021-12-31 | CN¥2.27 Billion ≈ $332.76 Million |
CN¥432.36 Million ≈ $63.27 Million |
0.190x | +105.44% |
| 2020-12-31 | CN¥2.00 Billion ≈ $293.25 Million |
CN¥185.47 Million ≈ $27.14 Million |
0.093x | -31.05% |
| 2019-12-31 | CN¥1.68 Billion ≈ $246.08 Million |
CN¥225.73 Million ≈ $33.03 Million |
0.134x | -0.76% |
| 2018-12-31 | CN¥1.38 Billion ≈ $202.40 Million |
CN¥187.10 Million ≈ $27.38 Million |
0.135x | -19.10% |
| 2017-12-31 | CN¥1.15 Billion ≈ $167.95 Million |
CN¥191.91 Million ≈ $28.08 Million |
0.167x | -63.22% |
| 2016-12-31 | CN¥342.96 Million ≈ $50.19 Million |
CN¥155.91 Million ≈ $22.82 Million |
0.455x | +0.31% |
| 2015-12-31 | CN¥268.60 Million ≈ $39.30 Million |
CN¥121.73 Million ≈ $17.81 Million |
0.453x | -24.02% |
| 2014-12-31 | CN¥165.19 Million ≈ $24.17 Million |
CN¥98.53 Million ≈ $14.42 Million |
0.596x | -16.03% |
| 2013-12-31 | CN¥84.06 Million ≈ $12.30 Million |
CN¥59.72 Million ≈ $8.74 Million |
0.710x | +21.27% |
| 2012-12-31 | CN¥40.63 Million ≈ $5.95 Million |
CN¥23.80 Million ≈ $3.48 Million |
0.586x | -- |
About Getein Biotech Inc
Getein Biotech, Inc researches, develops, produces, and sells in vitro diagnostic reagents and instruments in China and internationally. The company provides point-of-care detection, chemiluminescence detection, biochemical analysis, molecular testing, thrombus and hemostasis detection, blood cell analysis detection, urine analysis, quality control products, diagnostic raw materials, biochemical … Read more